News - Aricept

Filter

Current filters:

Aricept

Popular Filters

Eisai seeks expanded Japanese indication for Aricept

Eisai seeks expanded Japanese indication for Aricept

01-11-2013

Japanese drug major Eisai says it has filed an application for its already marketed anti-Alzheimer's…

AriceptAsia-PacificEisaiNeurologicalPharmaceuticalRegulation

Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales

29-10-2013

Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

Insights on the US Alzheimer's disease market

03-12-2012

The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

25-11-2012

The patent expiry of all four existing European Medicines Agency-approved drugs for Alzheimer's disease…

AriceptEbixaEisaiEuropeExelon PatchLundbeckMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalResearch

Public Citizen sues FDA for failing to ban dangerous dose of Aricept

07-09-2012

The Food and Drug Administration has dragged its feet for too long on a petition calling on the agency…

AriceptEisaiLegalNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Actavis to debut generic Aricept in EU markets as patents expire

16-02-2012

Icelandic generics firm Actavis yesterday announced the launch of donepezil, a generic copy of Eisai…

ActavisAriceptdonepezilEisaiEuropeGenericsMarkets & MarketingNeurologicalPfizer

Eisai wins patent extension in Japan for blockbuster Alzheimer’s drug Aricept

15-09-2011

Japanese drug major Eisai (TYO: 4523) says that the Supreme Court of Japan has turned down a petition…

AriceptAsia-PacificEisaiGenericsNeurologicalPatentsPharmaceutical

Back to top